Lung biopsy systems market seen hitting $5.4 billion by 2033

Persistence Market Research says the global lung biopsy systems market is set to grow from $3.3 billion in 2026 to $5.4 billion by 2033, driven by early lung disease detection, minimally invasive procedures and imaging advances. North America remains the leading region, while high equipment costs and procedure risks continue to slow broader adoption.

Why it matters: - Lung biopsy systems are becoming more important as providers push for earlier diagnosis of lung cancer and other respiratory diseases. - The market outlook signals steady demand for less invasive, more precise diagnostic tools across hospitals and specialty centers. - Growth in precision medicine is increasing the need for accurate tissue diagnosis.

What happened: - Persistence Market Research estimates the global lung biopsy systems market will rise from US$ 3.3 billion in 2026 to US$ 5.4 billion by 2033. - The report projects a 5.9% compound annual growth rate from 2026 to 2033. - The analysis says needle biopsy systems lead the product mix. - Hospitals remain the largest end-user segment. - North America is expected to stay the top regional market. - The report includes a free sample at More information. - The firm also offers report customization at Customize this report. - The full report is available at Buy the full report.

The details: - Needle biopsy systems hold the largest share because they are minimally invasive, offer high diagnostic accuracy and reduce recovery time. - Forceps biopsy systems and other specialized instruments support narrower clinical needs. - Image-guided biopsy procedures are gaining preference because they improve precision and help reduce complications. - Hospitals dominate because they handle high procedure volumes and have advanced diagnostic equipment. - Specialty clinics and diagnostic centers are expanding as patients look for faster diagnostic services. - Rising investment in healthcare infrastructure and access to skilled pulmonologists are supporting broader adoption. - The report says North America leads because of strong healthcare infrastructure, higher screening rates, favorable reimbursement and widespread use of advanced diagnostic technologies. - Europe remains a significant market on the back of early-diagnosis awareness and wider access to minimally invasive procedures. - Asia Pacific is emerging as the fastest-growing region as healthcare infrastructure, spending and access improve.

Between the lines: - The market’s growth is being driven by a shift toward earlier detection and more targeted treatment pathways. - The same trend is also raising expectations for procedure safety, which favors systems that reduce complications. - High equipment costs remain a major barrier, especially for smaller facilities and budget-constrained health systems. - Lung biopsy procedures still carry risks including bleeding, pneumothorax and infection, which can discourage use. - A shortage of trained pulmonologists can limit procedural capacity in underserved regions. - Artificial intelligence, robotic assistance and navigation systems could become key differentiators if they improve accuracy and lower risk.

What’s next: - Manufacturers are likely to keep focusing on precision medicine applications and technology upgrades. - Adoption should expand as governments invest in diagnostic infrastructure and cancer screening. - Collaboration between device makers and healthcare providers may speed deployment in emerging markets. - North America is expected to remain the largest market, while Asia Pacific should see faster growth than mature regions.

The bottom line: - Lung biopsy systems are on a steady growth path, but wider adoption will depend on whether providers can balance higher diagnostic precision with cost, training and procedure-risk hurdles.